Akero Therapeutics, Inc. Common Stock (AKRO)
Akero Therapeutics, Inc. is a biotechnology company focused on developing transformative therapies for chronic metabolic diseases, including non-alcoholic steatohepatitis (NASH). Founded to leverage its expertise in liver biology and medicinal chemistry, Akero aims to address areas with significant unmet medical needs through innovative drug candidates targeting liver fat accumulation and inflammation.
Company News
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches in several corporate sales involving trueCar, Akero Therapeutics, PotlatchDeltic, and Astria Therapeutics.
Novo Nordisk plans to acquire Akero Therapeutics for $4.7 billion, expanding its obesity and metabolic health treatment portfolio. The company is positioning itself competitively in the GLP-1 drug market, with an expected market growth from $15 billion in 2024 to $150 billion by 2034.
Novo Nordisk will acquire Akero Therapeutics for $54 per share in cash, totaling approximately $4.7 billion, with potential additional payment of $0.5 billion upon U.S. regulatory approval of EFX for treating liver disease.
Akero Therapeutics, a biotech company developing a potential treatment for a liver disease, saw its stock soar 97% after positive midstage clinical trial results. The article discusses the company's pipeline, the unmet need in this area, and the potential for accelerated approval, while also noting the risks involved as Akero's only pipeline cand...
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.